Literature DB >> 2794781

Detoxification of lithocholic acid. Elucidation of the pathways of oxidative metabolism in rat liver microsomes.

P Zimniak1, E J Holsztynska, R Lester, D J Waxman, A Radominska.   

Abstract

The hydroxylation of lithocholic acid (3 alpha-hydroxy-5 beta-cholanoic acid) by adult male Sprague-Dawley rat liver microsomes supplemented with NADPH was studied. Metabolites were separated by a combination of thin-layer chromatography and high pressure liquid chromatography, both with and without prior methylation and acetylation of the samples. The resulting products were characterized by thin-layer, gas-liquid, and high pressure liquid chromatography by comparison with authentic bile acid standards; final structure determination was by proton nuclear magnetic resonance spectroscopy and by mass spectrometry. The following reaction products were found: 3 alpha, 6 beta-dihydroxy-5 beta-cholanoic acid (80% of total metabolites) and 3 alpha, 6 alpha-dihydroxy-5 beta-cholanoic, 3 alpha, 7 alpha-dihydroxy-5 beta-cholanoic, 3 alpha, 6 beta,7 beta-trihydroxy-5 beta-cholanoic, and 3 alpha-hydroxy-6-oxo-5 beta-cholanoic acids (less than or equal to 5% each). In addition, one unidentified trihydroxylic bile acid and several minor compounds were present. It is concluded that four different hydroxylation reactions of lithocholic acid, namely the predominant 6 beta as well as the minor 6 alpha, 7 alpha, and 7 beta hydroxylations, are catalyzed by rat hepatic microsomes; 7 beta-hydroxylation may occur only with dihydroxylated bile acids but not with lithocholate itself. The presence of the 6-oxo bile acid can be explained either by direct oxidation of a hydroxyl group by cytochrome P-450, or by the action of microsomal dehydrogenase(s) which could also catalyze the epimerization of hydroxyl groups via their oxidation. The results form the basis of a proposed scheme of the oxidative metabolism of lithocholic acid in rat liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794781

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Ten Reasons to Think about Bile Acids in Managing Inflammatory Bowel Disease.

Authors:  Michael Camilleri
Journal:  J Crohns Colitis       Date:  2020-08-31       Impact factor: 9.071

2.  Distinct forms of cytochrome P-450 are responsible for 6 beta-hydroxylation of bile acids and of neutral steroids.

Authors:  P Zimniak; E J Holsztynska; A Radominska; M Iscan; R Lester; D J Waxman
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

3.  The lithocholic acid 6 beta-hydroxylase cytochrome P-450, CYP 3A10, is an active catalyst of steroid-hormone 6 beta-hydroxylation.

Authors:  T K Chang; J Teixeira; G Gil; D J Waxman
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

Review 4.  Lipid-activated transcription factors control bile acid glucuronidation.

Authors:  Olivier Barbier; Jocelyn Trottier; Jenny Kaeding; Patrick Caron; Mélanie Verreault
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

5.  Effect of chitosan feeding on intestinal bile acid metabolism in rats.

Authors:  Y Fukada; K Kimura; Y Ayaki
Journal:  Lipids       Date:  1991-05       Impact factor: 1.880

6.  Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions.

Authors:  Edik M Blais; Kristopher D Rawls; Bonnie V Dougherty; Zhuo I Li; Glynis L Kolling; Ping Ye; Anders Wallqvist; Jason A Papin
Journal:  Nat Commun       Date:  2017-02-08       Impact factor: 14.919

Review 7.  The Effect of Lithocholic Acid on the Gut-Liver Axis.

Authors:  Wei Sheng; Guang Ji; Li Zhang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

8.  Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice.

Authors:  Francesca Ferlenghi; Carmine Giorgio; Matteo Incerti; Lorenzo Guidetti; Paola Chiodelli; Marco Rusnati; Massimiliano Tognolini; Federica Vacondio; Marco Mor; Alessio Lodola
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.